1 / 34

Myasthenia Gravis

Myasthenia Gravis. Victor Politi,M.D. Medical Director, SVCMC School of Allied Health, Physician Assistant Program. Pathophysiology. The underlying defect is a decrease in the number of available Ach receptors at neuromuscular junctions due to an antibody mediated autoimmune attack.

kellsie
Download Presentation

Myasthenia Gravis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Myasthenia Gravis Victor Politi,M.D. Medical Director, SVCMC School of Allied Health, Physician Assistant Program

  2. Pathophysiology • The underlying defect is a decrease in the number of available Ach receptors at neuromuscular junctions due to an antibody mediated autoimmune attack

  3. Pathophysiology • Pathophysiology • ACh synthesized in the motor nerve terminal and stored in vesicles • ACh released causes miniature end plate potentials • Action potential release ACh and combined with postsynaptic receptors • Postsynaptic channels are open allowing entry of sodium producing depolarization of muscle fiber

  4. Pathophysiology • A process is terminated by hydrolysis of ACh by AChE • The fundamental defect is a decrease in the number of ACh receptors at the postsynaptic muscle membrane, therefore, although ACh is released normally it produces small end plate potentials which fail to trigger muscle action potentials

  5. MG- Autoantibodies protect against the postsynaptic acetylcholine receptors

  6. Pathophysiology • The neuromuscular abnormalities caused by an autoimmune response mediated by specific anti AChR antibodies • These antibodies reduce the available AChR’s at neuromuscular junctions

  7. Myasthenia gravis (MG) • Neuromuscular disorder characterized by weakness and fatigability of skeletal muscles • There is no cure for MG but treatment is highly effective

  8. Pathology • The neuromuscular abnormalities in MG are brought about by an autoimmune response mediated by specific anti-AChR antibodies • the thymus is abnormal in approximately 75% of patients with MG • In 65% of patients the thymus is hyperplastic

  9. Clinical Features • Prevalence rate 1 in 10,000 people • Can affect any age group • women - peak incidence 20’s-30’s • men - peak incidence 50’s-60’s • Women affected more than men • Cardinal features - weakness and fatigability

  10. Clinical Features • Weakness typically increases during repeated use (fatigue) and may improve during rest or sleep • Course of MG - variable • Remissions - rarely complete or permanent

  11. Clinical Features • Unrelated infections or systemic disorders may lead to increased myasthenic weakness and may precipitate a “crisis” • A crisis is if weakness in respiration or swallowing becomes severe and respiratory assistance or intubation is necessary

  12. Clinical Features • Characteristic pattern of muscle weakness • early involvement -lids and extraocular muscles • diplopia and ptosis common initial complaints • Difficulty in swallowing may occur

  13. Clinical Features • In 85% of cases, weakness becomes generalized, affecting limb muscles as well • Limb weakness is often proximal and may be asymmetric • deep tendon reflexes are preserved

  14. Diagnosis and Evaluation • Suspect on basis of weakness and fatigability as previously described • No loss of reflexes or impairment of sensation or other neurologic function • Edrophonium- initial dose 2mg IV, second dose 8mg IV • ACh receptor antibody detectable in 80% of all myosthenic patients

  15. Differential Diagnosis • Several other conditions that cause weakness or the cranial and/or somatic musculature must be considered in the differential diagnosis of MG: • drug induced myasthenia, Lambert-Eaton myasthenic syndrome,neurasthenia • hyperthyroidism, botulism, intracranial mass lesions and progressive external ophthalmoplegia

  16. Differential Diagnosis • Drugs that may exacerbate MG • penicillamine • aminoglycoside antibiotics • procainamide

  17. Lambert-Eaton myasthenic syndrome • Presynaptic disorder of neuromuscular junction - causes muscle weakness similar to MG • proximal muscles of lower limbs most commonly affected • ptosis of the eyelids and diplopia in up to 70% of patients

  18. LES- Autoantibodies against the presynaptic voltage-gated calcium channels

  19. Lambert-Eaton myasthenic syndrome • MG and Lambert-Eaton myasthenic syndrome are readily distinguished • patients with Lambert-Eaton syndrome have depressed or absent reflexes, autonomic changes (dry mouth, impotence) and show incremental responses on repetitive nerve stimulation

  20. Lambert-Eaton myasthenic syndrome • LES is caused by auto antibody directed against calcium channels on the motor nerve terminals resulting in impaired release of ACh

  21. Lambert-Eaton myasthenic syndrome • Majority of patients with this syndrome have an associated malignancy - most commonly small cell carcinoma of the lung • The diagnosis of Lambert-Eaton may signal the presence of the tumor long before it would otherwise be detected

  22. Lambert-Eaton myasthenic syndrome • Treatment involves plasmapheresis and immunosuppression, as for MG

  23. Myasthenic patients have an increased incidence of several associated disorders • Thymic abnormalities - 75% of cases • thymoma • Hyperthyroidism - 3-8% of cases • may worsen the myasthenic weakness • other autoimmune disorders • blood tests for rheumatoid factor, antinuclear antibodies

  24. Thymoma on CT of chest

  25. Chronic infection of any kind can exacerbate MG • measurements of ventilatory function are valuable because of the frequency and seriousness of respiratory impairment in myasthenic patients

  26. Because of the side effects of glucocorticoids and other immunosuppressive agents used in the treatment of MG, a through medical history/exam should be made • Particular attention should be paid to evidence of chronic or latent infection (tuberculosis/hepatitis), HTN, diabetes, renal impairment, and glaucoma

  27. Therapy • The prognosis has improved greatly for MG cases due to advances in treatment • virtually all MG patients can be returned to productive lives with proper therapy

  28. Therapy • Anticholinesterase medications • pyridostigmine • immunosuppressive agents • glucocorticoids, azathiopriane • thymectomy • plasmapheresis

  29. Management of myasthenic crisis • Exacerbation of weakness sufficient to endanger life • respiratory failure • aspiration • The possibility that the deterioration should be due to excessive anti -ChE medication (cholinergic crisis) is best excluded by temporarily stopping anti-ChE drugs

  30. Management of myasthenic crisis • The most common cause of crisis is intercurrent infection • The myasthenic patient with fever and early infection should be treated like other immunocompromised patients with early antibiotic therapy, respiratory assistance, and pulmonary physiotherapy. Plasmapheresis is frequently helpful in hastening recovery

  31. Questions ??

More Related